Hany Massarany Sells 8,252 Shares of GenMark Diagnostics, Inc. (GNMK) Stock

GenMark Diagnostics, Inc. (NASDAQ:GNMK) insider Hany Massarany sold 8,252 shares of the company’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $4.74, for a total value of $39,114.48. Following the completion of the sale, the insider now directly owns 362,957 shares of the company’s stock, valued at $1,720,416.18. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.

Hany Massarany also recently made the following trade(s):

  • On Thursday, November 2nd, Hany Massarany sold 1,588 shares of GenMark Diagnostics stock. The shares were sold at an average price of $7.24, for a total value of $11,497.12.

GenMark Diagnostics, Inc. (NASDAQ GNMK) traded up $0.07 during trading hours on Tuesday, reaching $4.71. The company’s stock had a trading volume of 425,851 shares, compared to its average volume of 423,827. GenMark Diagnostics, Inc. has a 52-week low of $3.63 and a 52-week high of $13.67. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.97 and a quick ratio of 2.77.

GenMark Diagnostics (NASDAQ:GNMK) last released its quarterly earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). GenMark Diagnostics had a negative return on equity of 100.33% and a negative net margin of 116.76%. The firm had revenue of $11.60 million for the quarter, compared to analyst estimates of $14.56 million. During the same period last year, the company earned ($0.27) EPS. The company’s revenue was up 7.4% compared to the same quarter last year. sell-side analysts forecast that GenMark Diagnostics, Inc. will post -1.17 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Hany Massarany Sells 8,252 Shares of GenMark Diagnostics, Inc. (GNMK) Stock” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.com-unik.info/2017/11/21/hany-massarany-sells-8252-shares-of-genmark-diagnostics-inc-gnmk-stock.html.

A number of research firms recently issued reports on GNMK. Zacks Investment Research cut GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Tuesday, November 7th. Canaccord Genuity reissued a “buy” rating and set a $14.00 target price (down from $17.00) on shares of GenMark Diagnostics in a research note on Monday, August 7th. Needham & Company LLC reissued a “buy” rating and set a $15.00 target price (down from $17.00) on shares of GenMark Diagnostics in a research note on Wednesday, September 13th. BidaskClub cut GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. Finally, BTIG Research set a $11.00 target price on GenMark Diagnostics and gave the stock a “buy” rating in a research note on Monday. Two analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. GenMark Diagnostics currently has an average rating of “Hold” and a consensus price target of $11.80.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in GNMK. FMR LLC boosted its holdings in shares of GenMark Diagnostics by 13.6% in the 2nd quarter. FMR LLC now owns 8,020,502 shares of the medical equipment provider’s stock valued at $94,883,000 after buying an additional 962,822 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of GenMark Diagnostics by 15.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,097,767 shares of the medical equipment provider’s stock valued at $48,476,000 after buying an additional 559,629 shares during the last quarter. Marshall Wace North America L.P. boosted its holdings in shares of GenMark Diagnostics by 1,787.6% in the 2nd quarter. Marshall Wace North America L.P. now owns 544,020 shares of the medical equipment provider’s stock valued at $6,528,000 after buying an additional 515,200 shares during the last quarter. Artisan Partners Limited Partnership boosted its holdings in shares of GenMark Diagnostics by 25.2% in the 2nd quarter. Artisan Partners Limited Partnership now owns 2,252,831 shares of the medical equipment provider’s stock valued at $26,651,000 after buying an additional 453,329 shares during the last quarter. Finally, Jennison Associates LLC boosted its holdings in shares of GenMark Diagnostics by 14.3% in the 2nd quarter. Jennison Associates LLC now owns 3,541,747 shares of the medical equipment provider’s stock valued at $41,899,000 after buying an additional 443,005 shares during the last quarter.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

What are top analysts saying about GenMark Diagnostics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GenMark Diagnostics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit